DEZHAN HEALTHCARE COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.71 CNY | +0.74% |
|
-6.55% | -17.13% |
| Sales 2022 | 571M 78.8M | Sales 2023 | 498M 68.76M | Capitalization | 7.05B 973M |
|---|---|---|---|---|---|
| Net income 2022 | -46M -6.35M | Net income 2023 | 83M 11.46M | EV / Sales 2022 | 9.18 x |
| Net cash position 2022 | 2.99B 413M | Net cash position 2023 | 2.79B 385M | EV / Sales 2023 | 8.55 x |
| P/E ratio 2022 |
-175
x | P/E ratio 2023 |
85.6
x | Employees | 1,002 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 38.78% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.74% | ||
| 1 week | -6.55% | ||
| Current month | -6.55% | ||
| 1 month | -6.87% | ||
| 3 months | -1.81% | ||
| 6 months | -26.76% | ||
| Current year | -17.13% |
1 week
2.65
2.79
1 month
2.613.07
Current year
2.233.30
1 year
2.234.70
3 years
2.235.75
5 years
2.2311.85
10 years
2.2315.50
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Liu
CEO | Chief Executive Officer | 54 | 16-10-27 |
Jing Hong Zhang
DFI | Director of Finance/CFO | 50 | 16-10-27 |
| 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xin An Wang
BRD | Director/Board Member | 60 | 21-08-30 |
Weihong Sun
BRD | Director/Board Member | 61 | 21-08-30 |
Feng Han
BRD | Director/Board Member | 54 | 10-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 2.71 | +0.74% | 14 878 400 |
| 24-04-22 | 2.69 | -0.37% | 16,437,900 |
| 24-04-19 | 2.7 | -1.10% | 14,753,200 |
| 24-04-18 | 2.73 | -1.44% | 22,134,930 |
| 24-04-17 | 2.77 | +6.13% | 37,702,290 |
End-of-day quote Shenzhen S.E., April 22, 2024
More quotes
Dezhan HealthCare Co Ltd, formerly Xinjiang Tianshan Wool Tex Stock Co Ltd, is a China-based company mainly engaged in the research and development, production and sales of pharmaceuticals. The Company focuses on cardiovascular and cerebrovascular drugs, anti-cancer drugs, health care products, functional beverages, ecological water and other fields. Its subsidiaries optimize the structure of combined products, introduce production lines that meet the production needs of multiple dosage forms according to product development needs, and increase products such as injections, biopharmaceuticals, and Chinese medicine preparations. The Company mainly conducts its businesses in the China market.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.13% | 804M | |
| +27.74% | 659B | |
| +27.68% | 557B | |
| -4.22% | 359B | |
| +16.46% | 322B | |
| +9.09% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.65% | 149B |
- Stock Market
- Equities
- 000813 Stock
